IKNA Ikena Oncology Operating Sales Margin

Symbol and logo of brand Ikena Oncology Inc. (IKNA)

Ikena Oncology, Inc. (IKNA) develops targeted therapies, aiming for global scaling through outsourcing, although funding shortages and the risk of failed trials threaten its capital. The operating margin trend clearly demonstrates business efficiency, where 0.00 reflects the latest metric value. Anticipation of data on new molecules remains the primary catalyst, as cost optimization is already priced in by the market.

Ikena (IKNA): Operating Return on Sales from 07/04/2022 to 08/09/2025

Analytical breakdowns for Ikena Oncology, Inc.

- share price and consensus valuation forecast:
Fundamental company analysis:IKNA, Ikena Oncology
Finished products of Ikena Oncology Inc.

To build a high-quality portfolio, I evaluate the operating margin as the ratio of operating profit to revenue, which determines cost management efficiency before accounting for financial leverage and taxes. In the case of Ikena Oncology, Inc. (IKNA), a negative operating margin reflects the high cost of developing targeted drugs and a reliance on external financing due to capital burn.

Key competitors

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|AONC (aoncology.com) - Return on Sales by Operating Profit|BGNE: Operating Margin|Checkpoint Therapeutics Inc (CKPT) - Operating Margin|ELEV (Elevation Oncology Inc.) - Operating Margin|icadmed.com (ICAD) - Profitability of Operations|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin